1. Home
  2. YDKG vs PPCB Comparison

YDKG vs PPCB Comparison

Compare YDKG & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yueda Digital Holding Class A Ordinary Share

YDKG

Yueda Digital Holding Class A Ordinary Share

N/A

Current Price

$0.84

Market Cap

4.9M

ML Signal

N/A

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.19

Market Cap

5.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
YDKG
PPCB
Founded
2005
2007
Country
China
Australia
Employees
N/A
N/A
Industry
Advertising
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
5.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
YDKG
PPCB
Price
$0.84
$0.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
164.2K
2.9M
Earning Date
03-06-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2175.52
N/A
52 Week Low
$0.79
$0.16
52 Week High
$669.00
$11.00

Technical Indicators

Market Signals
Indicator
YDKG
PPCB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
YDKG
PPCB

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: